Daniel Zelterman

Yale University — United States

Medicine · Health Sciences

54h-index12.6kcitations389works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(42), Statistical Methods and Bayesian Inference(37), Bayesian Methods and Mixture Models(30), Statistical Methods in Clinical Trials(29), Lung Cancer Treatments and Mutations(27)

Publications389 total

Change-Point Homogeneity in Piecewise Exponential Survival
Journal of Statistical Theory and Practice·2026
A joint distribution for indexes of extremes with applications to climate change
Statistics and Its Interface·2026
The Maximum Negative Hypergeometric Distribution
Journal of Statistical Theory and Practice·2025
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
JAMA Oncology·2024· 25 citedOpen Access
A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling
Statistics in Medicine·2024· 3 citedOpen Access
Abstract A002: A phase II study of peri-operative modified FOLFIRINOX in localized pancreatic ductal adenocarcinoma (PDAC)
Cancer Research·2024
Distributions and Their Approximations for p-Values
2024· 3 cited
Laparotomy versus Peritoneal Drainage for Necrotizing Enterocolitis and Perforation
2023· 3 cited
Data from DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy
2023Open Access
Data from DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy
2023Open Access
Supplemental Figures from DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy
2023Open Access
Supplemental Figures from DNA Polymerase Beta Germline Variant Confers Cellular Response to Cisplatin Therapy
2023Open Access
Supplementary Data from The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
2023Open Access
Data from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
2023Open Access
Supplemental Figure 2A from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
2023Open Access
Trial Protocol from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
2023Open Access
Table S5 from Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
2023Open Access
Supplemental Figure 1A from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
2023Open Access
Supplemental Figure 1C from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
2023Open Access
Supplemental Figure 1B from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
2023Open Access
page 1 of 20Next →

Frequent Co-authors

Scott Gettinger(5), Sunitha Nallur(4), Frank J. Slack(4), Joanne B. Weidhaas(4), Sarah B. Goldberg(4), Katerina Politi(4), Roy S. Herbst(4), David L. Rimm(4), Thomas Rutherford(4), Elena Ratner(3), Wei Wei(3), Harriet M. Kluger(3), Trupti Paranjape(3), Dennis Cooper(3), Lena J. Chin(2), Yongxue Zhu(2), Bruce G. Haffty(2), Lynn D. Wilson(2), Jungmin Choi(2), Anna Wurtz(2)